Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ImmunoCellular Therapeutics, Ltd. (IMUC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2998-0.0002 (-0.07%)
At close: 12:27PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3000
Open0.3000
Bid0.0000 x 900
Ask0.0000 x 3000
Day's Range0.2998 - 0.3000
52 Week Range0.1400 - 0.7500
Volume652
Avg. Volume3,561
Market Cap1.257M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.6900
Earnings DateAug 24, 2017 - Aug 25, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement

    EOM Pharmaceuticals, Inc. ("EOM"), a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) ("ImmunoCellular") today announced that the companies have entered into and closed on a merger agreement pursuant to which the shareholders of EOM are now the majority shareholders of the combined company. The merger will create a public company that will continue EOM's focus on advancing novel immunomodulatory and retinal disease drug agents to address a

  • PR Newswire

    ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market

    ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021. The amended Rule requires issuers that trade on the Over-the-Counter Link® Alternative Trading System or OTC Link ATS trading platform to make current information about the issuer publicly available. In advance of the deadline of June 30, 2021, ImmunoCellular has sub

Advertisement
Advertisement